Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window

Clin Neurol Neurosurg. 2011 Nov;113(9):768-73. doi: 10.1016/j.clineuro.2011.08.010. Epub 2011 Sep 4.

Abstract

Objective: To determine the safety and efficacy of combined local mild hypothermia and IV rtPA in treating acute ischemic stroke (AIS) patients with MRI perfusion- and diffusion-weighted imaging (PWI/DWI) mismatch within a 6-h stroke window.

Methods: AIS patients within 6 h of a minimum 20% PWI/DWI MRI mismatch were randomly assigned to 3 groups: local mild hypothermia with IV rtPA (Group A); IV rtPA (Group B); or conventional anti-platelet aggregation (Group C). Mortality and National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) score and Barthel Index (BI) were used in evaluation.

Results: There were significant differences in NIHSS 24 h after treatment among the three groups (P<0.001). Based on mRS and BI, more patients in Groups A and B showed favorable outcomes than patients in Group C (P=0.017 and P=0.009, respectively); however, there were no significant efficacy differences between Groups A and B. The incidence of symptomatic ICH and the mortality rates within 90 days in the 3 groups were similar. In addition, there were no significant differences in NIHSS improvement at 24 h and favorable outcomes 90 days after IV rtPA treatment between patients within 3 h and 3-6 h from symptom onset.

Conclusions: There was no benefit of combined local hypothermia/IV rtPA treatment compared to IV rtPA alone. PWI/DWI mismatching on MRI can be a selection criteria for IV rtPA treatment within a 6-h window.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Diffusion Magnetic Resonance Imaging
  • Female
  • Humans
  • Hypothermia, Induced* / adverse effects
  • Image Processing, Computer-Assisted
  • Magnetic Resonance Angiography
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Stroke / drug therapy
  • Stroke / mortality
  • Stroke / therapy*
  • Thrombolytic Therapy* / adverse effects
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Tissue Plasminogen Activator